Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

brodalumab (Siliq)

Initiation (new start) criteria and criteria for *new members* entering Kaiser Permanente already taking the medication who have not been reviewed previously:

Non-Formulary **brodalumab (Siliq)** will be covered on the prescription drug benefit for when the following criteria are met:

- 1. Prescriber is a dermatologist and patient has a diagnosis of psoriasis
 - Patient has tried and failed/intolerant to at least 2 of the following:
 - Adalimumab (criteria based)
 - Etanercept (criteria based)
 - Infliximab product
 - Patient has tried and failed/intolerant to or has contraindication to all of the following:
 - Secukinumab (criteria based)
 - Ustekinumab (criteria based)
 - o Apremilast (criteria based)
 - o Guselkumab (criteria based)
 - Patient does NOT have a diagnosis of Crohn's disease
 - Prescriber has completed the Prescriber Certification for Siliq REMS

kp.org

Revised: 02/13/20 Effective: 03/05/20 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest

